A number of studies have reported that variants in somatic SETD2 gene are related to the occurrence of a variety of tumors, especially renal cell carcinoma, pulmonary adenocarcinoma, enteropathy-associated T cell lymphoma, chronic lymphocytic leukemia, and gastrointestinal stromal tumors (D'Avella et al., 2020; Tessema et al., 2018; Moffitt et al., 2017; Parker et al., 2016; Huang et al., 2016). Here, SETD2 is linked to hereditary clear cell renal cell carcinoma.